Changing Landscape of the Cancer Genome

描述(由申请人提供)：本提案请求支持由Lynda Chin、Christoph Lengauer和Michael Stratton组织的题为改变癌症基因组景观的Keystone研讨会，该会议将于2011年6月20-25日在马萨诸塞州波士顿举行。全球范围内的大规模癌症基因组学项目正在捕捉到癌症基因组越来越详细的图像。这些数据有可能改变癌症研究的方方面面。现在的挑战是破译基因组图景告诉我们关于肿瘤的起源、发展和临床行为的是什么。这将是第一次专门关注大规模癌症基因组学项目的会议。除了对癌症的关注外，还有对基因组和计算技术的强烈重视。这次会议的目标如下：1)将数据生产者和分析师聚集在一起，分享他们从大规模癌症基因组项目中获得的最新技术和生物学发现，并解决分析这些复杂的癌症基因组数据的挑战；2)强调这些基因组数据是如何使系统或网络视角成为基因组的，以及在这些复杂网络的背景下，突变模式如何揭示潜在病因学的新见解；以及3)探索癌症基因组学如何影响药物的发现和开发。 与公共健康相关：国际大型基因组中心正在识别越来越多的标记和调节因子，这些标记和调节因子可能会将正常细胞转化为肿瘤细胞。这些数据的巨大数量带来了技术挑战，这就需要迅速发展新的数据处理技术。此外，基因组癌症标志物的鉴定与有效药物开发的最终翻译终点之间存在着巨大的差距。关于改变癌症基因组格局的Keystone研讨会会议填补了科学界的需求，为那些通过开展大规模癌症基因组学项目而采取雄心勃勃的癌症研究方法的研究人员和那些对使用数据感兴趣的人提供了一个论坛。

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Changing Landscape of the Cancer Genome, organized by Lynda Chin, Christoph Lengauer and Michael Stratton, which will be held in Boston, Massachusetts from June 20 - 25, 2011. Large scale cancer genomics projects across the globe are capturing increasingly detailed views of the cancer genomes. These data have the potential to transform every aspect of cancer research. The challenges now are to decipher what the genomic landscape is teaching us about the initiation, progression and clinical behavior of a tumor. This meeting will be the first with a singular focus on large scale cancer genomics projects. In addition to a focus on cancer, there is a strong emphasis on genomic and computational technologies. The goals of this meeting are as follows: 1) to bring together the data producers and analysts to share their latest findings, both technical and biological, from large-scale cancer genomic projects and address the challenges of analyzing these complex cancer genomic data; 2) to highlight how these genomic data are enabling a systems or network-view of the genome and how patterns of mutations, considered in the context of these complex networks, are revealing new insight into underlying etiologies; and 3) to explore how cancer genomics can impact on drug discovery and development. PUBLIC HEALTH RELEVANCE: International large-scale genome centers are identifying an ever-growing number of markers and regulators that can potentially transform normal cells into tumor cells. The sheer volume of these data presents technical challenges which require the rapid evolution of novel data-handling techniques. In addition, a wide gap exists between the identification of genomic cancer markers and the ultimate translational endpoint of efficacious drug development. The Keystone Symposia meeting on Changing Landscape of the Cancer Genome fills a need in the scientific community by providing a forum for those researchers who are taking an ambitious approach towards cancer research by conducting large-scale cancer genomics projects and those interested in using the data.